NLRP3 modulators
This disclosure features compounds of Formula I, or a pharmaceutically acceptable salt thereof: in which R 1 , R 2 , R 3 , and R 4 are as defined herein. These compounds are modulators of NLRP3, which are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
1. A compound selected from:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound or salt as claimed in claim 1 and one or more pharmaceutically acceptable excipients.
3. A method of treating melanoma or basal cell carcinoma, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in claim 1 .
4. The method of claim 3 , wherein the compound is administered in combination with one or more additional cancer therapies.
5. The method of claim 4 , wherein the one or more additional cancer therapies comprises surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy, or a combination thereof.